PAD

Global Carboxy Therapy Market Analysis and Forecast to 2028, by Type, Application, End User and Region - ResearchAndMarkets.com

Retrieved on: 
星期二, 十二月 26, 2023
Health, Other Health, Skin, UNDP, Tabletop, Digital, CVI, Pain management, Midaeium, Aesthetics, Hair loss, Prevalence, Wound healing, Ageing, Hospital, Incidence, Region, Cellulite, DSM-IV codes, Social media, Growth, System, Safety, Calibration, Carboxytherapy, PAD, Pharmaceutical industry

The "Global Carboxy Therapy Market: Analysis and Trends by Type, Application, End User and Region and Forecast up to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Carboxy Therapy Market: Analysis and Trends by Type, Application, End User and Region and Forecast up to 2028" report has been added to ResearchAndMarkets.com's offering.
  • The global carboxy therapy market value in 2022 stood at US$95.64 million, and is likely to reach US$191.32 million by 2028.
  • Carboxytherapy is well-suited to address these issues, making it a desirable option for the aging demographic, leading to the growth of carboxy therapy market.
  • Global Carboxy therapy Market Dynamics:
    Growth Drivers: Versatile application has the potential to boost the growth of the carboxy therapy market.

Humacyte Third Quarter 2023 Financial Results and Business Update

Retrieved on: 
星期四, 十一月 9, 2023
Sale, Trauma, Patient, Nationwide Children's Hospital, Research, Conference, Infection, Military personnel, Human, Food, Conference call, Journal, Clinical professor, HUMA, Moyamoya disease, Trial of the century, Extremities, BLA, PAD, Buddha's hand, Amputation, Injury, Saphenous, Chin Na, Patent, Gunshot, Polytetrafluoroethylene, Clinical trial, Peripheral artery disease, Chronic limb threatening ischemia, HAV, Dialysis, FDA, Success, File, Survival, Mayo Clinic, Accident, Hospital, Pharmaceutical industry, Medical device, Tetralogy of Fallot

DURHAM, N.C., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced financial results for the third quarter ended September 30, 2023 and highlighted recent corporate accomplishments advancing the investigational, universally implantable Human Acellular Vessel (HAV) closer to planned U.S. market launch.

Key Points: 
  • In addition, we recently published preclinical results of our small caliber HAV in a juvenile heart disease model.
  • Planned BLA Filing this Quarter – Humacyte plans to file a BLA for the HAV for the treatment of vascular trauma with the FDA during the current quarter.
  • There was no revenue for the third quarter of 2023 and nine months ended September 30, 2023.
  • The decrease in other net expense for the third quarter of 2023 compared to 2022 resulted primarily from an increase in interest income due to rate increases.

Exscientia Receives Open Philanthropy Grant to Explore New Therapeutic Approach for Pandemic Influenza

Retrieved on: 
星期二, 十二月 5, 2023
Health, Infectious Diseases, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Pandemic, Novo Nordisk Foundation, Global health, Research, Open Philanthropy (organization), PAD, Bill, Epithelium, COVID-19, Therapy, Science, Virus, Infection, Cell, Antiviral drug, Pharmaceutical industry, Vaccine

Exscientia plc (Nasdaq: EXAI) announced today that the Company received a $2.3 million grant from Open Philanthropy, a philanthropic funder with several programs in global health and wellbeing.

Key Points: 
  • Exscientia plc (Nasdaq: EXAI) announced today that the Company received a $2.3 million grant from Open Philanthropy, a philanthropic funder with several programs in global health and wellbeing.
  • Under this grant, Exscientia aims to harness the activation of the host interferon response as a therapeutic approach for pandemic influenza.
  • The grant comes in the context of the wider Pandemic Antiviral Discovery (PAD) initiative.
  • This focus aligns with the company’s ongoing commitment to pandemic preparedness, initiated with support from the Bill & Melinda Gates Foundation in 2021.

Surmodics Announces TRANSCEND Trial 36-Month Data Presented at 50th Annual VEITH Symposium

Retrieved on: 
星期四, 十一月 16, 2023
Cardiology, Biotechnology, Other Health, Health, General Health, Other Science, Medical Devices, Research, Hospitals, Science, Clinical Trials, Paclitaxel, TLA, Safety, PAD, Clinical trial, Patient, DCB, Thrombosis, Death, Freedom, Popliteal artery, Pharmaceutical industry, Czech Republic

Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that 36-month data from its TRANSCEND clinical trial was presented by Dr. Peter A. Schneider at the 50th Annual VEITH Symposium in New York, New York.

Key Points: 
  • Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that 36-month data from its TRANSCEND clinical trial was presented by Dr. Peter A. Schneider at the 50th Annual VEITH Symposium in New York, New York.
  • The TRANSCEND trial is a prospective, multi-center, single-blind, randomized, controlled trial to assess the safety and efficacy of the SurVeil™ drug coated balloon (DCB) versus the IN.PACT® Admiral® DCB for treatment of superficial femoral and proximal popliteal artery lesions.
  • The primary efficacy endpoint is 12-month primary patency, defined as freedom from binary restenosis or clinically driven target lesion revascularization (CD-TLR).
  • “The TRANSCEND 36-Month data continues to demonstrate safe and effective performance of the SurVeil DCB.

Bioresorbable Stents Global Strategic Market Report 2023 - ResearchAndMarkets.com

Retrieved on: 
星期三, 十一月 15, 2023
Surgery, Medical Devices, Health, Cardiology, Medical Supplies, Abbott Laboratories, PAD, Boston Scientific, Peripheral artery disease, CAD, Growth, Metal, Coronary artery disease, Bioresorbable stent, Hospital, Stent

The "Bioresorbable Stents - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Bioresorbable Stents - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
  • The global market for Bioresorbable Stents estimated at US$390.2 Million in the year 2022, is projected to reach a revised size of US$990.5 Million by 2030, growing at a CAGR of 12.4% over the analysis period 2022-2030.
  • The report delves into the overall market analysis, covering the period from 2020 to 2030, offering valuable insights for stakeholders in the bioresorbable stents industry.
  • This report also presents a comprehensive analysis of the global bioresorbable stents market, focusing on Europe, Asia-Pacific, and the Rest of the World regions.

MyKnowledgeMap Announces Electronic Practice Assessment Document Approved for SCPHN Programmes

Retrieved on: 
星期四, 十二月 14, 2023
Medicine, Trinity College London ESOL, Assistant, Middlesex University, City University, Education, PAD, Chair, Brunel University London, Buckinghamshire New University, NMC, Learning, Student, Health Education England, Bournemouth University, HEI, Canterbury Christ Church University, Ulster University, University, Sheffield Hallam University, King's College London, University of Surrey, HEE, UNICEF, Knowledge, Nursing, University of Northampton, University of Bolton, Northern Ireland

YORK, England, Dec. 14, 2023 /PRNewswire/ -- MyProgress is a workplace-based assessment and eportfolio tool designed specifically for medicine and healthcare education and is already used to support pre-registration nursing, nursing associate, and midwifery programmes around the capital at Pan London institutions, and at universities throughout the UK.

Key Points: 
  • Learning technology specialist MyKnowledgeMap is thrilled to announce the practice assessment document (PAD) it co-developed for SCPHN programmes has received NMC approval.
  • Nurses and midwives who take an approved SCPHN programme, and achieve the standards of proficiency, will join the SCPHN part of the NMC's register.
  • The introduction of the new standards requires all institutions with SCPHN programmes to obtain programme reapproval from the NMC for programmes starting no later than September 2024.
  • The developed practice assessment document has now been tested with practice partners and approved by the NMC following submission by one of the Pan London universities.

The American Diabetes Association Releases the Standards of Care in Diabetes--2024

Retrieved on: 
星期一, 十二月 11, 2023
Epidemiology, AID, Standard of care, Infection, PPC, Gestational diabetes, Diagnosis, CVD, Disability, Doctor of Philosophy, Mental health, Abridgement, Prediabetes, Diabetes, Knowledge, Webcast, NAFLD, RSV, Endocrinology, Fatty liver disease, Kidney disease, Cardiovascular disease, Fracture, Moyamoya disease, Society, Physician, Public, Hypoglycemia, Waist, Practitioner, PAD, Risk, Pharmacist, GIP, C-peptide, Artificial intelligence, Immunization, Conditional sentence, Section 4, Body mass index, Himawari (satellites), Classification, The Obesity Society, American Diabetes Association, Vaccine, Obesity, American College, Heart failure, COVID-19, Dietary supplement, Nursing, Landscape maintenance, Pharmaceutical industry, Medical device, Dentistry, MD

ARLINGTON, Va., Dec. 11, 2023  /PRNewswire/ -- Today, the American Diabetes Association® (ADA) released the Standards of Care in Diabetes—2024 (Standards of Care), a set of comprehensive and evidence-based guidelines for managing type 1, type 2, gestational diabetes, and prediabetes based on the latest scientific research and clinical trials. It includes strategies for diagnosing and treating diabetes in both youth and adults, methods to prevent or delay type 2 diabetes and its associated comorbidities like cardiovascular disease (CVD) and obesity, and therapeutic approaches aimed at minimizing complications and enhancing health outcomes.

Key Points: 
  • "The latest ADA guidelines present pivotal updates for health care professionals, ensuring comprehensive, evidence-based care for diabetes management.
  • "The ADA's Standards of Care ensures health care professionals, especially our primary care workforce, provide the best possible care to those living with diabetes."
  • The Standards of Care are critical to ensuring the improved treatment of diabetes, a chronic disease that requires continuous care through a well-informed and coordinated health care team.
  • Today, the Standards of Care in Diabetes—2024 is available online and is published as a supplement to the January 2024 issue of Diabetes Care® .

Accura Scan, The Only Certified Biometric Solution Provider in Middle East & Africa for Banks and Telcos

Retrieved on: 
星期四, 十二月 7, 2023
YP, 3D, DNA, PAD, Ambition, ISO/IEC, Telecommunications, Alpha beta filter, ISO, Algorithm, USD, Digital, Mask, FAR, Account verification, FRR, Security printing, Cryptocurrency, MENA

Commenting on this feat, Director - International Sales, Reza Writer, added, "Ambition greater than resources is in the DNA of Accura Scan.

Key Points: 
  • Commenting on this feat, Director - International Sales, Reza Writer, added, "Ambition greater than resources is in the DNA of Accura Scan.
  • The ISO 30107-3 framework measures a biometric system's false acceptance rate (FAR) and false rejection rate (FRR) at the point of presentation.
  • Passing the evaluation with an FAR of 0%, means that the company's biometric algorithms offer a high level of spoof resistance in all environments.
  • With top-notch Identity Verification & Digital KYC products, it is confident of making a mark in these markets.

Accura Scan, The Only Certified Biometric Solution Provider in Middle East & Africa for Banks and Telcos

Retrieved on: 
星期四, 十二月 7, 2023
YP, 3D, DNA, PAD, Ambition, ISO/IEC, Telecommunications, Alpha beta filter, ISO, Algorithm, USD, Digital, Mask, FAR, Account verification, FRR, Security printing, Cryptocurrency, MENA

Commenting on this feat, Director - International Sales, Reza Writer, added, "Ambition greater than resources is in the DNA of Accura Scan.

Key Points: 
  • Commenting on this feat, Director - International Sales, Reza Writer, added, "Ambition greater than resources is in the DNA of Accura Scan.
  • The ISO 30107-3 framework measures a biometric system's false acceptance rate (FAR) and false rejection rate (FRR) at the point of presentation.
  • Passing the evaluation with an FAR of 0%, means that the company's biometric algorithms offer a high level of spoof resistance in all environments.
  • With top-notch Identity Verification & Digital KYC products, it is confident of making a mark in these markets.

Payroc Expands Payments Platform in the United States and Canada

Retrieved on: 
星期四, 十一月 30, 2023
ACH, Independent software vendor, API, A2A, Micro ISV, Friction, PAD, Ecosystem, Bank

TINLEY PARK, Ill., Nov. 30, 2023 /PRNewswire-PRWeb/ -- Payroc, a leading payment processing platform, announces the expansion of its payment solution, now available in the United States and Canada. The PayByBank offering empowers Independent Software Vendors (ISVs) and merchants to accept token-based card and bank payments through a single interface enabling recurring, Account-to-Account (A2A) payments with tokenization.

Key Points: 
  • This expansion allows partners to accept tokenized card and bank payments in both the United States and Canada, which ensures maximum security for both one-time and recurring payments.
  • TINLEY PARK, Ill., Nov. 30, 2023 /PRNewswire-PRWeb/ -- Payroc, a leading payment processing platform, announces the expansion of its payment solution, now available in the United States and Canada.
  • We believe this release will unlock significant growth opportunities for partners operating in both the United States and Canada."
  • By integrating once, partners gain access to a unified payment infrastructure that spans both the United States and Canada.